摘要
目的观察沃丽汀对糖尿病肾病大鼠肾脏的保护作用,并探讨其作用机制。方法将雄性Wistar大鼠随机分为正常对照组(NC组),糖尿病肾病组(DN组)和沃丽汀治疗组(D+J组)各10只。DN组与D+J组采用链脲佐菌素(STZ)诱导制作糖尿病大鼠模型。模型制作成功后,NC组与DN组给予0.9%氯化钠溶液10 mL.kg-1灌胃,D+J组于模型制作成功后第3天开始给予沃丽汀灌胃,0.9 mg.kg-1.d-1。8周后采用放免法检测大鼠血浆降钙素基因相关肽(CGRP)含量,免疫组织化学方法检测肾小球血管内皮生长因子(VEGF)表达情况,同时检测24 h尿清蛋白排泄率(24hUAER)、尿肌酐清除率(Ccr)、肾重指数(KMI)、体重及血糖。结果与NC组比较,DN组血浆中CGRP水平、Ccr及体重均显著降低(均P<0.01),24 hUAER、KMI、肾脏VEGF表达及血糖均显著升高(均P<0.01)。与DN组比较,D+J组CGRP水平差异无显著性,Ccr显著升高(P<0.05),肾脏VEGF表达显著降低(P<0.01)。结论沃丽汀对糖尿病肾病大鼠血浆CGRP水平无显著影响,但能抑制肾组织VEGF表达,一定程度上延缓糖尿病肾病发展。
Objective To investigate the protective effects of Jolethin on rats with experimental diabetic nephropathy and the possible mechanism underlying. Methods Thirty male Wistar rats were randomly divided into three groups： the normal control （ NC ）, rats with diabetic nephropathy （ DN ） and diabetic rats treated with Jolethin （ D ＋ J ）. The rat model of diabetes mellitus was produced by injection of streptozocin（ STZ）3 days after, rats in D ＋ J group were treated with Jolethin 0. 9 mg · kg^-1 · d^-1. After 8 weeks of the treatment, plasma levels of CGRP was measured by radioimmunoassay; the expression of VEGF in glomeruli were detected by immunohistochemical technique ; UAER, Ccr, kidney weight / body weight （ KMI）, body weight and blood glucose for 24 h were measured as well. Results Compared with those in the NC group,the plasma CGRP, Ccr and body weight were significant decreased （ P 〈 0. 01 ）, nevertheless, the UAER, KMI, renal expression of VEGF and blood glucose for 24 h were obviously increased（ P 〈 0. 01 ）in the DN group. Compared with those in the DN group, rats in D ＋ J had significant higher Ccr （P 〈 0.05 ） and significant lower renal expression of VEGF （ P 〈 0. 01 ）, except for CGRP. Conclusion Jolethin has no significant effect on secretion of CGRP,but suppresses the overproduction of VEGF, which leading to prevention against diabetic nephropathy.
出处
《医药导报》
CAS
2008年第11期1314-1317,共4页
Herald of Medicine
